Joao V. Alessi

Also affiliated with Hospital Sírio-Libanês

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 23 papers. Top paper: “Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC”.

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1420

N/A

0.787DataRank · unranked

189 citations

Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou +61 more

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.07.005

N/A

0.701DataRank · unranked

106 citations

Joao V. Alessi, Arielle Elkrief, Xinan Wang, Alessio Cortellini, Y Y Li +27 more

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1207

N/A

0.542DataRank · unranked

36 citations

Biagio Ricciuti, Chaitanya Bandlamudi, Daniel M. Muldoon, Hira Rizvi, Arielle Elkrief +23 more

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Nature Communications(2023)10.1038/s41467-023-39874-8

N/A

0.515DataRank · unranked

30 citations

Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti +13 more

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-006994

N/A

0.416DataRank · unranked

15 citations

Joao V. Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul +16 more

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer

The Oncologist(2023)10.1093/oncolo/oyad197

N/A

0.385DataRank · unranked

12 citations

Biagio Ricciuti, Joao V. Alessi, Teng Fei, Hannah L. Kalvin, Jacklynn V. Egger +16 more

Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.07.121

N/A

0.373DataRank · unranked

11 citations

Alessandro Di Federico, Bolun Liu, Alissa J. Cooper, Joao V. Alessi, Phoebe Clark +25 more

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007618

N/A

0.330DataRank · unranked

8 citations

Adam Price, Allison L. Richards, Biagio Ricciuti, Xinan Wang, Arielle Elkrief +14 more

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2990

N/A

0.312DataRank · unranked

7 citations

Rohit Thummalapalli, Stephanie Alden, Biagio Ricciuti, Joao V. Alessi, Arielle Elkrief +18 more

Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer

Human Genetics and Genomics Advances(2024)10.1016/j.xhgg.2024.100320

N/A

0.269DataRank · unranked

5 citations

Kangcheng Hou, Biagio Ricciuti, Joao V. Alessi, Xihao Li, Federica Pecci +8 more

Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.09.18.613595

N/A

0.104DataRank · unranked

1 citations

Georgia L. Stirtz, Asaf Tal, Ajit J. Nirmal, N. Besson, Stephanie M. Jones +34 more

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001007

N/A

0DataRank · unranked

59 citations

Biagio Ricciuti, E. Jimenez-Aguilar, Fangxin Hong, Zihan Wei, Mizuki Nishino +10 more

Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.03.045

N/A

0DataRank · unranked

5 citations

Federica Pecci, Biagio Ricciuti, Felix H. Gottlieb, Francesco Facchinetti, Guilherme Harada +21 more

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.10.013

N/A

0DataRank · unranked

374 citations

Kathryn C. Arbour, W. Marston Linehan, Amir Vajdi, Natalie I. Vokes, Lingzhi Hong +28 more

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab116

N/A

0DataRank · unranked

68 citations

Biagio Ricciuti, Joao V. Alessi, Tom Nguyen, Mark M. Awad, Xihong Lin +3 more

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors

Nature Communications(2022)10.1038/s41467-022-33210-2

N/A

0DataRank · unranked

28 citations

Geoffrey R. Oxnard, Elizabeth F. Cohen, Navin R. Mahadevan, Joao V. Alessi, Yin P. Hung +18 more

Germline variants associated with immunotherapy-related adverse events

medRxiv(2022)10.1101/2022.04.10.22273627

N/A

0DataRank · unranked

0 citations

Sarah Abou Alaiwi, Wenxin Xu, Vivek Naranbhai, Amin H. Nassar, Ziad Bakouny +26 more

Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancers

Research Square(2022)10.21203/rs.3.rs-2273813/v1

N/A

0DataRank · unranked

0 citations

Biagio Ricciuti, Xinan Wang, Giuseppe Lamberti, Arielle Elkrief, Federica Pecci +12 more

Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden

Cancer Cell(2023)10.1016/j.ccell.2023.09.006

N/A

0DataRank · unranked

60 citations

Jiwoong Kim, Qing Deng, Biagio Ricciuti, Joao V. Alessi, Buse Eglenen-Polat +12 more

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib

JCO Precision Oncology(2023)10.1200/po.23.00295

N/A

0DataRank · unranked

5 citations

Biagio Ricciuti, Guilherme Harada, Matteo Repetto, Melissa Gildenberg, Ankit Singh +16 more

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers

Nature Communications(2024)10.1038/s41467-024-49499-0

N/A

0DataRank · unranked

13 citations

Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti, Joao V. Alessi +6 more

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers

Research Square(2024)10.21203/rs.3.rs-3782958/v1

N/A

0DataRank · unranked

1 citations

Taek-Chin Cheong, Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti +6 more

CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success

Cell(2025)10.1016/j.cell.2025.09.021

N/A

0DataRank · unranked

11 citations

Georgia L. Stirtz, Asaf Tal, Ajit J. Nirmal, Kathleen L. Pfaff, Michael P. Manos +39 more